Company / Depreciation & Amortization
Compass Therapeutics, Inc. Depreciation & Amortization History
FY2019-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Depreciation & Amortization
$589.0K
FY2024
5-year range
$566.0K / $2.4M
FY2020-FY2024
Trend
-15.7%
vs FY2023
Sector context
#137 of 177
Health Care
What the data says
Compass Therapeutics, Inc.'s depreciation & amortization of $589,000 is lower than 77% of companies in the Health Care sector (FY2024). Depreciation & Amortization has fluctuated over the past 6 years, ranging from $566,000 in FY2021 to $2M in FY2020.
Based on SEC 10-K filings.
$589,000 in FY2024 with a 5-year CAGR of -22.5%.
Improved from $782,000 to $589,000 over the past 2 years.
Health Care sector context is included.
Depreciation & Amortization over time
Growth rates
- 3-Year CAGR
- +1.3%
- 5-Year CAGR
- -22.5%
- 10-Year CAGR
- -
Sector benchmark
-99.7% below sector average
Key checks
Key Insights
- 5-year CAGR of -22.5%, indicating a declining trend.
- In FY2024, depreciation & amortization decreased 15.7% year-over-year.
- Ranks #137 out of 177 companies in the Health Care sector.
- Peak depreciation & amortization was recorded in FY2020.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Depreciation & AmortizationValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $589.0K | -15.7% |
| FY2023 | $699.0K | -10.6% |
| FY2022 | $782.0K | +38.2% |
| FY2021 | $566.0K | -76.4% |
| FY2020 | $2.4M | +14.3% |
| FY2019 | $2.1M | - |
| FY2018 | - | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026